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Background: Breast cancer stem cells with a CD44+CD24- phenotype are the origin of breast 
tumors. Strong CD44 expression in this population indicates its important role in maintaining 
the stem cell phenotype. Previous studies show that CD44 down-regulation causes CD44+CD24- 
breast cancer stem cells to differentiate into non-stem cells that are sensitive to antitumor drugs 
and lose many characteristics of the original cells. In this study, we determined tumor suppression 
in non-obese severe combined immunodeficiency mice using CD44 shRNA therapy combined 
with doxorubicin treatment.
Methods: Tumor-bearing non-obese severe combined immunodeficiency mice were established 
by injection of CD44+CD24- cells. To track CD44+CD24- cells, green fluorescence protein 
was stably transduced using a lentiviral vector prior to injection into mice. The amount of 
CD44 shRNA lentiviral vector used for transduction was based on CD44 down-regulation by 
in vitro CD44 shRNA transduction. Mice were treated with direct injection of CD44 shRNA 
lentiviral vector into tumors followed by doxorubicin administration after 48 hours. The effect 
was evaluated by changes in the size and weight of tumors compared with that of the control.
Results: The combination of CD44 down-regulation and doxorubicin strongly suppressed tumor 
growth with significant differences in tumor sizes and weights compared with that of CD44 
down-regulation or doxorubicin treatment alone. In the combination of CD44 down-regulation 
and doxorubicin group, the tumor weight was significantly decreased by 4.38-fold compared 
with that of the control group.
Conclusion: These results support a new strategy for breast cancer treatment by combining 
gene therapy with chemotherapy.
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Introduction
CD44+CD24- cells have been identified as a breast cancer stem cell population and 
the origin of tumors, metastasis, and relapse in breast cancer patients.1–3 Breast cancer 
stem cell targeting is considered a promising therapy. Thus far, various drugs that are 
specific to receptors such as Her2/neu and epidermal growth factor receptors have 
been used to target breast cancer stem cells.4–11 However, more than 50% of tumors 
do not express these receptors and are drug resistant.12–16 A recent report has shown 
that triple-negative breast carcinoma contains CD44+CD24- breast cancer stem cells.17 
Therefore, it is essential for treatment that new targets be discovered on breast cancer 
stem cells.
CD44 plays an important role in the phenotype of breast cancer stem cells and 
is responsible for cancer stem cell-specific characteristics, such as antitumor drug 
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resistance in various cancers like colon cancer,18 salivary 
gland cancer,19 and metastasis from the breast to the liver.20 
In addition, CD44 has been used to isolate and enrich cells 
that are capable of forming breast cancer tumors21 and 
numerous other tumors, including head and neck squamous 
cell carcinoma,22–24 esophageal squamous cell carcinoma,25 
nasopharyngeal carcinoma,26 and gastric27 and colon cancer 
stem cells.28
Down-regulation of CD44 using siRNA or shRNA 
results in metastasis suppression,29 sensitizes cancer stem 
cells to drugs,30 and causes differentiation of breast cancer 
stem cells.31 Antibodies against survivin also show similar 
effects.32 CD44 also plays an important role in other cancers. 
CD44 inhibition suppresses the development of colon tumors 
in mice33 and inhibits the proliferation and metastasis of 
ovarian34 and liver cancer cells.35 This study evaluates breast 
cancer treatment in mouse models using a CD44 shRNA 
lentiviral vector to inhibit CD44 expression in combination 
with doxorubicin chemotherapy.
Materials and methods
Cell culture and establishment of green 
fluorescent protein (GFP)-expressing 
breast cancer stem cells
Breast cancer stem cells were isolated and purified as 
described elsewhere.30 Briefly, tumor biopsies from 
consenting patients were obtained at hospitals and then 
transferred to our laboratory. Biopsy samples were washed 
3–4 times with phosphate-buffered saline containing 
1 × antibiotic-antimycotic (Sigma, St Louis, MO), and 
then homogenized into small pieces (approximately 
1–2 mm3). Homogenized samples were resuspended in 
M171 medium (Invitrogen, Carlsbad, CA) containing 
mammary epithelial growth supplement (Invitrogen) and 
then seeded in 35 mm culture dishes (Nunc, Germany). 
Cells were incubated at 37°C with 5% CO2, and medium 
was replaced every third day. CD44+CD24- cells were iso-
lated from the primary cell population by magnetic sorting 
using a commercial kit (Miltenyi Biotec,   Germany). These 
CD44+CD24- cells were named BCSC1. For tracking, 
we established CD44+CD24- cells that stably expressed 
the gfp gene. We used a gfp lentiviral vector (Santa Cruz 
Biotechnology, CA) to transduce isolated CD44+CD24- 
cells. To select and establish GFP-expressing BCSC1, 
cells were cultured in medium containing 10 µg/mL 
puromycin dihydrochloride (Sigma-Aldrich, St Louis, 
MO) for 1 week.
CD44 knockdown of CD44+CD24- cells 
with shRNA using lentivirus particles
In the first assay, we determined a suitable dose of lentiviral 
particle vector infectious units (IFUs) to apply in the next 
experiment. CD44 shRNA lentivirus particles (Santa Cruz 
Biotechnology, Inc, Santa Cruz, CA) were stably trans-
fected according to the manufacturer’s instructions. Briefly, 
BCSC1 cells were seeded on day 1 in a twelve-well plate 
with complete medium (Dulbecco’s modified Eagle’s 
medium/F12 supplemented with 10% fetal bovine serum and 
1 × antibiotic-mycotic) and incubated overnight.
Medium was replaced on day 2 with fresh complete 
medium containing 5 µg/mL polybrene (Sigma-Aldrich, 
St Louis, MO) for 6 hours, then 20 µL of modified Eagle’s 
medium with 25 mM 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid containing 1 × 105 IFUs of virus was added 
to the culture. The culture plate was shaken to mix the virus 
particles and was then incubated overnight at 37°C with 5% 
CO2. On day 3, medium was replaced with fresh complete 
medium without polybrene. Half of the transduced cells were 
confirmed by CD44 detection using flow cytometry. Half of 
the transduced cells were selected by culturing in complete 
medium containing 10 µg/mL puromycin dihydrochloride for 
12 hours, followed by 5 µg/mL puromycin dihydrochloride 
for 1 week.
Flow cytometry
Cells were washed twice in phosphate-buffered saline 
containing 1% bovine serum albumin (Sigma-Aldrich, 
St Louis, MO). Fc receptors were blocked by incubation with 
immunoglobulin G (Santa Cruz Biotechnology, CA) on ice for 
15 minutes. Cells were stained with anti-CD44-PE monoclonal 
antibodies (BD Biosciences, Franklin Lakes, NJ) at 4°C for 
30 minutes. After washing, cells were analyzed using a FAC 
SCalibur flow cytometer (BD Biosciences) and CellQuest 
Pro software (BD Biosciences) with 10,000 events collected.
CD44 shRNA gene therapy
Female (5–6 weeks old) NOD/severe combined immuno-
deficiency (SCID) mice (NOD.CB17-Prkdcscid/J; Charles 
River Laboratories, Wilmington, MA) were subcutane-
ously injected with BCSC1 cells (2 × 106 cells/mouse). 
After 2 weeks, tumors were formed and mice were divided 
into four groups: Group 1 (control) mice (n = 4) were 
used as untreated controls; they received biweekly intra-
tumoral phosphate-buffered saline injections for 6 weeks. 
Group 2 (doxorubicin [Dox]) mice received intratumoral Dox 
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  injections (2 mg/kg) weekly for 4 weeks. Group 3 (shRNA) 
mice received intratumoral CD44 shRNA lentiviral vector 
injections with a dose of IFUs that was doubled compared 
with that of the tumor cell number. Group 4 (CD44 shRNA 
in combination with Dox treatment [shRNA + Dox]) mice 
received intratumoral injections of CD44 shRNA lentivi-
ral vector with IFUs similar to that of Group 3 and, after 
48 hours, received intratumoral injections of Dox (2 mg/kg) 
weekly for 4 weeks. Tumor size was measured as described 
below. Animals were killed after 7 weeks, and tumors were 
excised and weighed to record the wet tumor weight. All ani-
mal experiments were approved by the Institutional Animal   
Care and Use Committee of Stem Cell Research and Appli-
cation Laboratory, University of Science, VNU-HCM.
Tumor size measurement
Tumor size was measured with calipers in two dimensions, 
and size was calculated using the following formula: a × b2/2, 
where “a” is the tumor length and “b” is the diameter.36
Statistical analysis
All experimental procedures were performed in triplicate, 
except for mouse experiments. The significance of differ-
ences between mean values was assessed by a Student’s 
t-test and analysis of variance. P , 0.05 was considered 
significant.
Results
Isolation and establishment of breast 
cancer stem cells expressing green 
fluorescent protein
We primary-cultured 31 tumor samples from patients; 23 of 
these samples showed numerous single cells surrounding 
the tumor tissue. Cells from the 23 samples were allowed to 
propagate to 80% confluence (Figure 1A). CD44 and CD24 
were analyzed and all 23 primary cell samples showed a small 
population of cells that were positive for CD44 and negative 
or weakly positive for CD24. This population constituted 
3.96% ± 1.72% of the total cells derived from primary cul-
ture. We isolated two populations of CD44+CD24- cells from 
the 23 primary-culture samples. One cell population, termed 
“BCSC1,” was used for subsequent experiments (Figure 1B). 
The BCSC1 cell line was transduced with the gfp gene 
using a lentiviral vector, resulting in 43.12% and 99.9% of 
BCSC1 cells expressing GFP before and after selection with 
puromycin, respectively (Figure 1C).
Tumor-bearing mouse models
To establish the tumor-bearing mouse models, we used 5–6-
week-old NOD/SCID mice. GFP-expressing BCSC1 cells 
(2.106 cells/mouse) were injected into mammary fat using 
an insulin needle. This resulted in 100% of mice forming 
tumors that were apparent after 3 weeks. All tumors contained 
GFP-expressing cells (Figure 2).
In vitro CD44 down-regulation  
by the CD44 shRNA lentiviral vector
Next, we evaluated in vitro CD44 down-regulation with 
CD44 shRNA using a lentiviral vector to determine a suit-
able dose for in vivo transduction. CD44 down-regulation 
was dependent on the ratio of IFUs to BCSC1 cells, with a 
higher ratio of lentiviral vector to BCSC1 cells resulting in 
higher transduction efficiency. The percentages of CD44 
down-regulated BCSC1 cells in the control (1:0), Dox (2:1), 
CD44 shRNA (1:1), and CD44 shRNA + Dox (1:2) groups 
were 0.14% ± 0.08%, 12.21% ± 3.30%, 37.87% ± 5.34%, 
and 47.41% ± 3.90%, respectively (P , 0.05) (Figure 3). 
Based on these results, the suitable dose of lentiviral vector 
IFUs was double that of the number of tumor cells. This dose 
was applied in further experimentation.
A B C
Figure 1 Breast cancer cells from breast tumors (A) were used to isolate CD44+CD24- breast cancer stem cell populations (B) for green fluorescent protein expression 
after transduction with green fluorescent protein using a lentiviral vector and selection with puromycin (C).
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Figure 2 A tumor produced in the mouse model. The tumor (A) was excised and observed by monochromatic fluorescence microscopy (Carl Zeiss AG, Oberkochen, 
Germany) using fluorescein isothiocyanate (B) and Hoechst 33342 filters (Carl Zeiss AG, Oberkochen, Germany) (C) for a merged image (D).
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Figure 3 In vitro CD44 down-regulation using the CD44 shRNA lentiviral vector with doses of infectious units to breast cancer stem cells at ratios 1:0 (A and E), 2:1   
(B and F), 1:1 (C and G) and 1:2 (D and H).
Tumor size and weight
As shown in Figure 4, the size and weight of tumors were 
significantly different between the four groups (P , 0.05). 
The average tumor sizes were 246.39 ± 56.80 mm3, 
142 ± 25.98 mm3, 80.89 ± 11.11 mm3, and 19.75 ± 8.50 mm3 
in the control, Dox, CD44 shRNA, and CD44 shRNA + Dox 
groups, respectively. In comparison with the control group, 
the tumor sizes were significantly decreased by 1.74-, 
3.04-, and 12.47-fold in the Dox, CD44 shRNA, and 
CD44 shRNA + Dox groups, respectively. Tumor weights 
also gradually decreased (0.44 ± 0.18 g, 0.23 ± 0.05 g, 
0.18 ± 0.02 g, and 0.1 ± 0.07 g). In CD44 shRNA + Dox, 
the tumor weight was significantly decreased by 4.38-fold 
compared with that of the control group. These changes in 
tumor size and weight confirmed the beneficial effects of 
CD44 down-regulation, Dox treatment, and particularly, the 
combination of CD44 down-regulation and Dox   treatment. 
Thus, combinatorial therapy of CD44 down-regulation 
and Dox efficiently suppressed tumor growth in the mouse 
model.
Discussion
Cancer stem cells are considered the origin of malignant 
tissues. The existence of cancer stem cells has been recently 
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confirmed in solid tumors of the brain, prostate, pancreas, 
liver, colon, head and neck, lung, and skin.36–42 Moreover, 
CD44+CD24- cells have been identified as breast cancer 
stem cells.21
Since the discovery of cancer stem cells, the study of 
cancer treatment in general, and breast cancer in particular, 
has gradually focused on targeting cancer stem cells. Thus 
far, targeting of breast cancer stem cells has been performed 
using various approaches, but has mainly targeted self-
renewal and differentiation of breast cancer stem cells. 
To influence self-renewal and differentiation, signaling 
pathways that are important in breast cancer stem cells, 
such as Wnt, Notch, and Hedgehog, can be targeted.43–46 
There are numerous methods to target signaling pathways, 
including gene therapy, immunotherapy, and targeting 
the cell environment. In our previous study, we found 
that CD44 down-regulation reduces the drug resistance 
of breast cancer stem cells to Dox.30 In previous research, 
we also confirmed that CD44 shRNA lentiviral particles 
reduced CD44 expression and caused breast cancer stem 
cell differentiation.31 In this study, we used an experimental 
treatment to target breast cancer stem cells by combining 
gene therapy targeting CD44 and Dox treatment.
First, we established a breast cancer stem cell line that 
stably expressed GFP to monitor the xenografted breast 
cancer tumor in mice. To establish this cell line, breast cancer 
stem cells were transduced with a lentiviral vector carrying 
gfp and a puromycin resistance gene for selection. Because 
random insertion of lentiviral DNA into the genome can 
cause detrimental mutations, we isolated CD44+CD24- cells 
from GFP-breast cancer stem cells using a magnetic cell 
separation method, and re-analyzed with flow cytometry. 
Indeed, a study showed that lentiviral vectors demonstrate a 
low tendency to integrate into genes that cause cancer,47 and 
another study found no increase in tumor incidence and no 
earlier onset of tumors in a mouse strain following the use 
of lentiviral vectors.48
These BSCS1 cells were used to evaluate the potential 
to form tumors in NOD/SCID mice and CD44 knockdown 
mice using a CD44 shRNA lentiviral vector as well as deter-
mination of the optimal dose of lentiviral particles for in vivo 
analyses. GFP-expressing BCSC1 maintained a tumorigenic 
capacity and formed malignant tumors in NOD/SCID mice 
with numerous poorly differentiated and abnormal cells.
Next, we determined the appropriate dose of virus par-
ticles to infect tumors, which was considered to be the IFUs 
that down-regulated CD44 at the highest rate. To determine 
the appropriate dose, we conducted serial assays with ratios 
between cells and IFUs at 2:1, 1:1, and 1:2. CD44 down-
regulation was highest using double the IFUs compared 
with that of the cell number. To determine the number of 
cells in a tumor, we measured the tumor size at the time of 
treatment. The number of tumor cells is calculated as 1 cm3 
tumor contains ∼1 × 109 cells.49 Although recent studies have 
supported this claim,50–52 experiments using the same mouse 
breed under the same conditions are necessary to apply this 
rule in calculation and comparison among the mice.
Lentiviral vector-injected mice were treated with Dox 
after 48 hours. This period was chosen because previous 
study has shown that viruses infect target cells and inhibit 
CD44 expression after 24 hours.30 The Dox dose used was 
2 mg/kg body weight and this was chosen based on a previ-
ous study.53
The results showed significant differences in the size and 
weight of tumors of treated mice compared with those of the 
controls. Dox treatment and CD44 siRNA therapy alone or in 
combination inhibited tumor growth. Tumor inhibition with 
Dox treatment and CD44 shRNA therapy alone was identical, 
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Figure 4 Tumor size and weight in experimental groups (A). Graphs of the differences in the size (B) and weight (C) of tumors in control, Dox, CD44 shRNA, and 
CD44 shRNA + Dox groups.
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while a significant difference (P , 0.05) was demonstrated 
between combinatorial therapy with Dox and CD44 shRNA 
compared with that of single treatments.
CD44 down-regulation also effects adhesion, invasion, 
and metastasis,54–59 and the inhibition of CD44 is also 
considered as treatment therapy in many cancer targets.57–59 
In addition, CD44 down-regulation that suppresses the 
development of tumors has also been shown in in vivo colon 
cancer tumors,33 ovarian cancer cells,34 and nasopharyngeal 
carcinoma cells.60–61 In recent research, we recognized 
that CD44 maintains the stemness of breast cancer stem 
cells. CD44 knocked-down breast cancer stem cells by 
CD44 shRNA lentiviral particles can cause differentiation 
of breast cancer stem cells or loss of stemness can change 
the tumor formation and metastasis related genes, and can 
reduce tumor formations in NOD/SCID mice.31
CD44 down-regulation using shRNA suppressed 
xenografted breast tumor growth in a mouse model with or 
without Dox treatment. However, there are limitations for the 
clinical application of this therapy. The two most significant 
issues are the host’s immune response to the lentiviral 
vector and random insertion mutagenesis. The immune 
response to the lentiviral vector is very low because viral 
proteins are not translated. Therefore, an immune response 
occurs only as a primary response to the virus or products 
of transgenes. In this study, the lentiviral vector was only 
transcribed into shRNA. Moreover, an immune response 
occurs only in response to adenoviral vectors or in the nature 
of the mechanism of adeno-associated viral production of 
antibodies against them,62 while lentiviral vectors possess 
many traits that enable avoidance of the immune response. 
As mentioned, insertion mutations caused by lentiviral 
vectors are fewer and less serious compared with those 
caused by other vectors. Insertion mutations have been 
detected in three out of eleven cross-linked SCID children 
after applying ex vivo therapy using a murine leukemia virus 
vector.63 Murine leukemia virus vectors are often inserted 
into promoters and CpG islands that affect transcriptionally 
active genes.64,65 Integrations near transcription start sites 
may increase oncogenesis, either by influencing the activity 
of host promoters or producing new full-length transcripts. 
In contrast, lentiviral vectors that integrate into the entire 
transcribed region are less likely to disturb the regulation 
and expression of host genes.66 This claim is supported by 
a Montini et al,48 which showed that lentiviral vectors cause 
insertion mutations related to cancer less often compared 
with murine leukemia virus vectors in a mouse model. 
However, these problems can be solved by using site-specific 
gene transfer. With the structural advantages of this vector 
system, cassettes that contain numerous genes can be 
expressed in the same vector, such as a Cre recombinase 
in combination with loxP sites or a zinc finger nuclease. 
However, there are some limitations in applying these results 
in clinical trials. First, the high dose of lentiviral vector can 
cause some side effects; in particular, lentiviral vectors can 
migrate into bone marrow to suppress the mesenchymal stem 
cells and other cells that strongly express CD44. Second, 
in practice, intratumoral delivery is not generally carried 
out. However, as many kinds of cells as well as stem cells 
strongly express CD44, we cannot apply systemic therapy 
in this case.
Conclusion
Strong CD44 expression in a breast cancer stem cell popu-
lation with a CD44+CD24- phenotype plays a pivotal role 
in the proliferation and drug resistance of malignant cells. 
Our data suggest that CD44 down-regulation suppresses 
tumor growth in a mouse model. Combinatorial therapy 
of CD44 down-regulation using a CD44 shRNA lentiviral 
vector and Dox treatment strongly inhibits tumor growth. 
These results support a new targeted therapy using gene 
therapy and chemotherapy to eradicate breast cancer stem 
cells. If this therapy is found to be safe, it may be a promis-
ing therapy for breast cancer through the targeting of breast 
cancer stem cells.
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